Market News (Page 17) - TendieTensor

Market News Page 17 of 234 • 5,844 articles

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

GlobeNewswire Inc. • Cytokinetics, Incorporated

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

12/19/2025 04:00 PM • Cytokinetics announced FDA approval of MYQORZO (aficamten), a cardiac myosin inhibitor for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval is based on the SEQUOIA-HCM Phase 3 trial, which demonstrated significant improvements in exercise capacity and symptom relief. The drug will be available in the U.S. in the second half of January 2026 and is subject to a REMS program due to heart failure risks. Cytokinetics also received NMPA approval in China and a positive opinion from the European Medicines Agency.

BMLpJ - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
CYTK - Company achieved its first FDA approval for MYQORZO, a significant milestone. The drug demonstrated robust efficacy in clinical trials with meaningful improvements in exercise capacity and symptom relief. Additional regulatory approvals in China and positive opinion from EMA provide further validation and expansion opportunities. The approval represents a major achievement for the company's pipeline and future revenue potential.

#FDA approval #MYQORZO #aficamten #cardiac myosin inhibitor #obstructive hypertrophic cardiomyopathy #oHCM #SEQUOIA-HCM trial #heart failure risk #REMS program #China NMPA approval #European Medicines Agency

TrustCo Bank Corp NY Announces Two-Million Share Stock Repurchase Program

GlobeNewswire Inc. • Na

TrustCo Bank Corp NY Announces Two-Million Share Stock Repurchase Program

12/19/2025 04:00 PM • TrustCo Bank Corp NY announced Board approval of a new stock repurchase program authorizing up to 2 million shares (approximately 11% of outstanding shares) to be repurchased over the next 12 months. The company completed a previous 1 million share buyback program in 2025. CEO Robert McCormick stated the repurchases reflect confidence in the company's business model and capital-building strategy, aimed at increasing shareholder value.

BMLpH - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
TRST - The company is executing a substantial share repurchase program (2 million shares, ~11% of outstanding), demonstrating management confidence in the business model and financial strength. The completion of a previous 1 million share buyback and announcement of strong financial metrics (26.3% net income increase, 11.5% net interest income growth) indicate solid operational performance and capital position to support shareholder returns.

#stock repurchase #share buyback #shareholder value #capital allocation #savings bank #dividend

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRGO

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – PRGO

12/19/2025 03:59 PM • Rosen Law Firm is urging investors who purchased Perrigo Company plc securities between February 27, 2023 and November 4, 2025 to join a class action lawsuit. The lawsuit alleges that Perrigo made false statements regarding its Nestlé-acquired infant formula business, which suffered from underinvestment, manufacturing deficiencies, and required substantial undisclosed capital expenditures, resulting in overstated financial results.

MERpK - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
PRGO - The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding its infant formula business operations, including underinvestment, manufacturing deficiencies, and overstated financial results. These allegations indicate significant corporate governance and operational failures that harmed investors.

#securities class action #Perrigo Company plc #infant formula business #misleading statements #financial misstatement #lead plaintiff deadline #investor compensation

ROSEN, LEADING INVESTOR COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JYD

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, LEADING INVESTOR COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JYD

12/19/2025 03:57 PM • Rosen Law Firm is encouraging investors who purchased Jayud Global Logistics Ltd. (NASDAQ: JYD) securities between April 21, 2023 and April 30, 2025 to join a class action lawsuit. The lawsuit alleges that Jayud engaged in a fraudulent stock promotion scheme involving social media misinformation, impersonated financial professionals, and coordinated share dumping by insiders using offshore accounts. The firm is seeking a lead plaintiff by the January 20, 2026 deadline.

JYD - The company is the subject of a securities class action lawsuit alleging fraudulent stock promotion schemes, insider share dumping, false statements, and misleading disclosures about its business operations and prospects.

#securities class action #fraudulent stock promotion #insider trading #share dumping #misleading statements #lead plaintiff deadline

Deal Dispatch: Snoopy, TikTok, Trump And The Weeknd Are In The Mix

Benzinga • Anthony Noto

Deal Dispatch: Snoopy, TikTok, Trump And The Weeknd Are In The Mix

12/19/2025 03:45 PM • Major M&A activity dominated the market with Trump Media merging with TAE Technologies in a $6B+ fusion energy deal, TikTok divesting U.S. operations to Oracle-led joint venture valued at $14B, Sony acquiring majority control of Peanuts IP for $457M, and The Weeknd closing a catalog investment deal with Lyric Capital. Global M&A surged 46% YoY to $4.4 trillion in 2025, marking the second-strongest year on record.

DJT - Stock rose on announcement of major $6B+ merger with TAE Technologies focused on fusion energy, demonstrating significant growth ambitions and market confidence despite existing debt burden.

#M&A #merger #acquisition #fusion energy #TikTok divestment #catalog deal #global deal activity

ROSEN, A TOP RANKED LAW FIRM, Encourages Bitdeer Technologies Group Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTDR

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A TOP RANKED LAW FIRM, Encourages Bitdeer Technologies Group Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTDR

12/19/2025 03:34 PM • A securities class action lawsuit has been filed against Bitdeer Technologies Group for allegedly providing misleading statements about its SEALMINER A4 Bitcoin mining machine and SEAL04 ASIC chip technology. The defendants allegedly failed to disclose material facts about production timelines and chip efficiency specifications, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is February 2, 2026.

BTDR - The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding its Bitcoin mining technology roadmap, specifically concerning the SEALMINER A4 project and SEAL04 chip specifications. Defendants allegedly made false statements while concealing material adverse facts, resulting in investors purchasing securities at artificially inflated prices.

#securities class action #Bitdeer Technologies #SEALMINER A4 #SEAL04 ASIC chip #misleading statements #investor damages #lead plaintiff deadline

ROSEN, A TOP RANKED LAW FIRM, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OWL

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A TOP RANKED LAW FIRM, Encourages Blue Owl Capital Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OWL

12/19/2025 03:33 PM • A securities class action lawsuit has been filed against Blue Owl Capital Inc. (OWL) alleging that defendants made false and misleading statements regarding BDC redemptions, undisclosed liquidity issues, and the company's true business prospects. Investors who purchased securities between February 6, 2025 and November 16, 2025 may be entitled to compensation. The lead plaintiff deadline is February 2, 2026.

JEF - Acting as a joint book-running manager for the offering, performing a standard financial service role
OWL - The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding BDC redemptions, liquidity issues, and business prospects. Investors claim they suffered damages when the true details entered the market.

#securities class action #Blue Owl Capital #BDC redemptions #liquidity issues #misleading statements #investor compensation #lead plaintiff deadline

Elizabeth Warren Warns Of 'Cloud Of Corruption' In Warner Bros. Buyout: Calls On Pam Bondi To Step Aside

Benzinga • Chris Katje

Elizabeth Warren Warns Of 'Cloud Of Corruption' In Warner Bros. Buyout: Calls On Pam Bondi To Step Aside

12/19/2025 03:31 PM • Senator Elizabeth Warren and Richard Blumenthal have called for Attorney General Pam Bondi to recuse herself from reviewing potential Warner Bros. Discovery acquisition deals by Netflix or Paramount Skydance, citing conflicts of interest. The senators point to Bondi's previous employment at lobbying firm Ballard Partners, which represents both bidders and has connections to the Trump Administration, raising concerns about potential impropriety in the deal review process.

WBD - The company is at the center of a controversy involving potential conflicts of interest and regulatory concerns, with calls for recusal of the Attorney General overseeing the deal review process.

#Warner Bros. Discovery #merger #conflict of interest #Pam Bondi #Elizabeth Warren #Netflix #Paramount Skydance #DOJ review #Ballard Partners #Trump Administration

INSP FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSP

GlobeNewswire Inc. • Rosen Law Firm

INSP FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSP

12/19/2025 02:58 PM • Rosen Law Firm is reminding investors in Inspire Medical Systems, Synopsys, and CarMax of upcoming lead plaintiff deadlines in securities class action lawsuits. The cases allege misrepresentations regarding product demand and market conditions, with investors potentially eligible for compensation through contingency fee arrangements.

BACpO - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
INSP - Company is subject to securities class action lawsuit alleging misrepresentation of market demand for Inspire V sleep apnea device and failure to disclose actual launch readiness, resulting in investor damages.

#securities class action #lead plaintiff deadline #investor compensation #misrepresentation #product launch

Third-Party Recognition Underscores Genesis Healthcare’s Ongoing Commitment to Excellence in Skilled Nursing Care

GlobeNewswire Inc. • Na

Third-Party Recognition Underscores Genesis Healthcare’s Ongoing Commitment to Excellence in Skilled Nursing Care

12/19/2025 02:55 PM • Genesis Healthcare announced that multiple affiliated skilled nursing facilities earned national recognition from U.S. News & World Report and Newsweek for 2026. Eleven Genesis-affiliated facilities were recognized by U.S. News & World Report as Best Nursing Homes, while four centers were named to Newsweek's America's Best Nursing Homes list. The recognitions are based on evaluations of clinical outcomes, staffing, patient experience, safety measures, and quality indicators.

BACpP - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
GENNQ - The company received multiple prestigious third-party recognitions from U.S. News & World Report and Newsweek for 2026, with 11 and 4 facilities respectively earning Best Nursing Homes designations. These independent validations of quality care, clinical outcomes, and operational excellence demonstrate strong performance and commitment to patient care standards.

#skilled nursing facilities #national recognition #quality care #operational excellence #clinical outcomes #patient experience #long-term care #short-term rehabilitation

DP World Welcomes New Gemini AL3 Service in Saint John, Expanding Transatlantic Trade Connectivity

GlobeNewswire Inc. • Dp World

DP World Welcomes New Gemini AL3 Service in Saint John, Expanding Transatlantic Trade Connectivity

12/19/2025 02:45 PM • DP World announced that the Gemini Cooperation's westbound AL3 container service will begin operations at Port Saint John in January 2026, providing direct import connectivity from Southampton, UK. The service complements the existing eastbound AL1 service, creating a dedicated transatlantic 'Powerlane' with sailing times of 9-10 days from Hamburg to Saint John, enhancing access to Canadian and U.S. Midwest markets through DP World's Express Rail Service partnership with CPKC.

BACpQ - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
CP - CPKC benefits from increased cargo volumes through its partnership with DP World's Express Rail Service, providing enhanced connectivity for inland North American markets through the new AL3 service.

#container shipping #transatlantic service #Port Saint John #import/export connectivity #rail logistics #Atlantic gateway

SNPS FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important December 30 Deadline in Securities Class Action - SNPS

GlobeNewswire Inc. • Rosen Law Firm

SNPS FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important December 30 Deadline in Securities Class Action - SNPS

12/19/2025 02:43 PM • Rosen Law Firm is reminding Synopsys investors of the December 30, 2025 deadline to join a securities class action lawsuit. The lawsuit alleges that Synopsys made materially false statements and failed to disclose that its increased focus on AI customers was deteriorating the economics of its Design IP business, negatively impacting financial results.

BACpS - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
SNPS - The company is the subject of a securities class action lawsuit alleging material misstatements and non-disclosure of adverse business impacts related to AI customer focus deteriorating Design IP economics, resulting in investor damages.

#securities class action #lead plaintiff deadline #material misstatement #AI customers #Design IP business #investor compensation

CARMAX IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages CarMax, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm – KMX

GlobeNewswire Inc. • Rosen Law Firm

CARMAX IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages CarMax, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm – KMX

12/19/2025 02:41 PM • Rosen Law Firm has filed a securities class action lawsuit against CarMax, Inc. for allegedly making materially false and misleading statements about growth prospects during the Class Period (June 20 - November 5, 2025). The lawsuit claims defendants recklessly overstated growth that was primarily driven by temporary tariff-related speculation rather than sustainable business fundamentals. Investors who purchased CarMax securities during this period may be eligible for compensation. The lead plaintiff deadline is January 2, 2026.

BMLpG - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
KMX - CarMax is the defendant in a securities class action lawsuit alleging material misstatements and misleading disclosures about growth prospects. The company allegedly overstated growth driven by temporary tariff-related customer speculation, indicating potential fraud and resulting investor damages.

#securities class action #CarMax #misleading statements #growth prospects #tariff speculation #investor compensation #lead plaintiff deadline

Class Action Reminder for SFM Investors: Kessler Topaz Meltzer & Check, LLP Reminds Sprouts Farmers Market, Inc. (SFM) Investors of Securities Fraud Class Action Lawsuit

GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

Class Action Reminder for SFM Investors: Kessler Topaz Meltzer & Check, LLP Reminds Sprouts Farmers Market, Inc. (SFM) Investors of Securities Fraud Class Action Lawsuit

12/19/2025 01:37 PM • A securities class action lawsuit has been filed against Sprouts Farmers Market, Inc. for allegedly making false and misleading statements about growth and stability. The complaint alleges the company overstated consumer resilience and growth projections while failing to disclose macroeconomic pressures. The lead plaintiff deadline is January 26, 2026.

BACpM - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
SFM - The company is accused of making false and misleading statements about business growth and stability, overstating consumer resilience, and failing to meet growth projections. These allegations of securities fraud and material misrepresentations directly harm investor confidence and indicate serious operational and disclosure failures.

#securities fraud #class action lawsuit #false statements #growth projections #macroeconomic pressures #lead plaintiff deadline

Nvidia Stock Climbs On Reports of US Review Of H200 Exports To China

Benzinga • Evette Mitkov

Nvidia Stock Climbs On Reports of US Review Of H200 Exports To China

12/19/2025 01:34 PM • Nvidia shares rose 2.95% on Friday following reports that the Trump administration has begun a formal review of H200 AI chip exports to China. The U.S. Commerce Department forwarded license applications to State, Energy, and Defense Departments for a 30-day review, with President Trump having final authority. Trump previously signaled willingness to allow H200 sales to China with a 25% government fee, arguing it could help U.S. chipmakers maintain competitive advantage. Multiple analysts maintain bullish ratings on Nvidia with increased price targets.

BACpN - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
NVDA - Stock price increased 2.95% on news of formal export review process for H200 chips to China. Potential approval could open significant new market opportunities. All five recent analyst ratings are bullish with increased price targets, with Tigress Financial raising target to $350 and Truist Securities to $275.

#H200 exports #China trade #AI chips #export review #Trump administration #semiconductor #geopolitical

Brighty Launches Cashback Service for Crypto Cards, Offering Up to 1.75% Back

GlobeNewswire Inc. • Not Specified

Brighty Launches Cashback Service for Crypto Cards, Offering Up to 1.75% Back

12/19/2025 01:00 PM • Brighty, a Lithuanian crypto-native digital finance platform, has launched a cashback program for VISA and MasterCard cards offering rewards across all user tiers without requiring platform token purchases. The program features tiered cashback rates (0.5%-1.75%) with bonus category unlocks based on spending, and is currently running a 2x multiplier promotion through January 18, 2026.

BACpE - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
V - Visa is mentioned only as a payment card partner integrated into Brighty's platform. There is no specific information about Visa's performance, strategy, or impact from this partnership.

#cashback program #digital nomads #crypto finance #VISA/MasterCard #European IBAN #stablecoin yields #blockchain technology

Meridianbet (GMGI) Sponsors Top European MMA Championship

GlobeNewswire Inc. • Na

Meridianbet (GMGI) Sponsors Top European MMA Championship

12/19/2025 12:49 PM • Meridianbet, a subsidiary of Golden Matrix Group, announced its title sponsorship of Fight Nation Championship (FNC 26) in Montenegro on December 20, 2025. The sponsorship leverages FNC's position as Europe's leading MMA promotion with 43 events and 272+ professional matches, serving as a talent pipeline for top-tier organizations. Meridianbet plans to integrate original programming and fighter partnerships to expand its sports media presence across its 18 operational jurisdictions.

BACpK - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
GMGI - Strategic sponsorship deal demonstrates expansion of Meridianbet's sports media platform across established markets (Serbia, Montenegro, Bosnia-Herzegovina) and positions the company as an integrated media operator beyond traditional betting, leveraging a $1.5B global MMA market opportunity.

#sports betting #MMA sponsorship #Fight Nation Championship #content strategy #regional expansion #sports media #fighter partnerships

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Benzinga • Vandana Singh

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

12/19/2025 12:43 PM • Merck & Co. has decided not to exercise its option for Evaxion's gonorrhea vaccine candidate EVX-B2 (protein-based version), allowing Evaxion to retain global rights and seek alternative licensing partners. The decision does not impact Evaxion's cash runway extending to mid-2027. Evaxion continues developing an mRNA version with Afrigen Biologics and previously out-licensed EVX-B3 to Merck in September for $7.5 million upfront plus up to $592 million in milestone payments.

BACpL - Maintains Buy rating and sees promising growth potential for Medtronic's medical technologies
EVAX - Merck's decision to opt out of the EVX-B2 protein-based vaccine represents a setback, requiring Evaxion to find a new partner. Stock declined 14.61% on the news. However, the company maintains cash runway and retains global rights to the candidate, providing some mitigation.

#gonorrhea vaccine #EVX-B2 #licensing partnership #biotech #vaccine development #mRNA vaccine #drug development

Umicore - Transparency notification by Bank of America Corporation

GlobeNewswire Inc. • Na

Umicore - Transparency notification by Bank of America Corporation

12/19/2025 12:30 PM • Bank of America Corporation, through its subsidiary Merrill Lynch International, has notified Umicore that it crossed below the 3% voting rights threshold on December 15, 2025. The holding now stands at 2.96% (0.29% direct voting rights and 2.67% equivalent financial instruments), down from the previous 3% threshold.

MU - Lost about 3.5% amid tech sector weakness
BAC - The notification reflects a routine reduction in holdings below a regulatory threshold. This is a standard disclosure event with no indication of strategic significance or market concern. The disposal appears to be a normal portfolio adjustment rather than a distress sale or major strategic shift.

#major holdings disclosure #voting rights threshold #Merrill Lynch International #share disposal #regulatory notification

Umicore - Transparantieverklaring van Bank of America Corporation

GlobeNewswire Inc. • Na

Umicore - Transparantieverklaring van Bank of America Corporation

12/19/2025 12:30 PM • Bank of America Corporation, through its subsidiary Merrill Lynch International, has exceeded the statutory 3% threshold of direct voting rights and equivalent financial instruments in Umicore as of December 15, 2025. The total holding amounts to 3.42%, comprising 0.29% direct voting rights and 2.67% equivalent financial instruments. The notification was filed on December 17, 2025, in accordance with Belgian disclosure regulations.

DXCM - Stock increased 6.7%, one of the top gainers in S&P 500
BAC - The notification is a routine regulatory disclosure of a shareholding threshold breach. There is no indication of strategic intent, hostile action, or material business impact. It is a factual reporting requirement with no inherent positive or negative implications for either party.

#shareholding disclosure #voting rights #financial instruments #regulatory notification #major holdings #threshold breach

Umicore - Déclaration de transparence par Bank of America Corporation

GlobeNewswire Inc. • Na

Umicore - Déclaration de transparence par Bank of America Corporation

12/19/2025 12:30 PM • Bank of America Corporation, through its subsidiary Merrill Lynch International, notified Umicore on December 17, 2025, that it crossed below the 3% legal threshold of voting rights and equivalent financial instruments on December 15, 2025. The total holding decreased to 2.96% (0.29% direct voting rights and 2.67% equivalent financial instruments), down from the previous 3.42% threshold.

CRWV - Tumbled 13% after trimming full-year revenue outlook
BAC - The notification reflects a routine regulatory disclosure of a downward threshold crossing in shareholding. This is a standard corporate action with no indication of positive or negative business implications. The decrease in holdings is a factual event requiring disclosure under transparency regulations.

#voting rights disclosure #shareholding notification #threshold crossing #financial instruments #transparency regulation

GlobeNewswire Inc. • Na

Transaction in Own Shares

12/19/2025 12:29 PM • Shell plc repurchased 1,967,666 shares on 19 December 2025 across multiple trading venues (LSEG and XAMS) at prices ranging from 26.58 to 30.90 GBP/EUR per share. The purchases are part of the company's existing share buyback programme authorized through 30 January 2026, with Merrill Lynch International managing trading decisions independently.

SHEL - Share buyback announcements are typically neutral signals. While buybacks can indicate management confidence in valuation and provide shareholder returns, they represent a routine capital allocation decision rather than material business news. The transaction is procedural in nature and conducted within pre-authorized parameters.

#share buyback #share repurchase #own shares #capital allocation #market regulation compliance #LSEG #XAMS

DEADLINE ALERT for DEFT, OWL, and BTDE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire Inc. • The Law Offices Of Frank R. Cruz

DEADLINE ALERT for DEFT, OWL, and BTDE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

12/19/2025 12:19 PM • Class action lawsuits have been filed against DeFi Technologies Inc. (DEFT), Blue Owl Capital Inc. (OWL), and Bitdeer Technologies Group (BTDR) for allegedly making materially false and misleading statements. DEFT faces allegations of undisclosed delays in its DeFi arbitrage strategy and overstated competition impact. OWL is accused of failing to disclose liquidity issues from BDC redemptions. BTDR allegedly misrepresented the readiness of its SEAL04 chip for mass production. Investors have until January 30, 2026 (DEFT) and February 2, 2026 (OWL and BTDR) to file lead plaintiff motions.

DEFT - Class action alleges material misstatements regarding delayed DeFi arbitrage strategy execution, understated competitive pressures, and failure to meet revenue guidance, indicating serious operational and disclosure issues.

#class action lawsuit #securities fraud #shareholder litigation #material misstatement #disclosure failure #investor losses

Reddit: Why Is It the New Growth Stock to Beat?

Investing.com • Nathan Reiff

Reddit: Why Is It the New Growth Stock to Beat?

12/19/2025 12:16 PM • Reddit has emerged as a standout growth stock in 2025, returning 37% year-to-date while competitors like Meta and Pinterest underperformed. The platform's strength is driven by impressive user engagement (116 million daily active users, up 20% YOY), surging revenue ($585 million, up 67% YOY), and international expansion. With ARPU at $5.04 (up 41% YOY) still significantly below competitors, Reddit has substantial room for monetization improvement. Analysts remain optimistic with 18 of 29 assigning Buy ratings, though the stock is nearing consensus price targets.

RDDT - Strong 37% YOY return, impressive 20% user growth to 116M DAU, 67% revenue growth to $585M, 400% EPS growth, and 31% international user growth. Significant ARPU upside potential ($5.04 vs Meta's ~$15) and analyst support (18 of 29 Buy ratings) indicate strong growth trajectory.

#user engagement #revenue growth #ARPU monetization #international expansion #AI opportunity #advertising momentum #daily active users

Morgan & Morgan Announces Record-Breaking Year Of Awards

GlobeNewswire Inc. • Not Specified

Morgan & Morgan Announces Record-Breaking Year Of Awards

12/19/2025 12:16 PM • Morgan & Morgan, America's largest injury law firm, announced it received hundreds of honors from leading legal publications in 2025, including recognition as the best Civil Rights/Discrimination firm by The National Law Journal's Elite Trial Lawyers. Over 240 firm attorneys were recognized by Super Lawyers, and the firm highlighted major achievements including a $425.7 million verdict against Google in a data privacy case.

GOOG - Google was ordered to pay $425.7 million in a data privacy verdict for surreptitiously collecting users' data without permission, representing a significant legal loss and potential reputational damage related to privacy practices.

#Morgan & Morgan #legal awards #injury law firm #data privacy litigation #Google verdict #attorney recognition #civil rights #mass torts